At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 25 enrolled
Drug / intervention
Afatinibdrug
Likely dose
Afatinib 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations
In Brief
A Phase 4 clinical trial evaluating Afatinib for Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Completed, enrolled 25 participants across 10 sites.
Detailed Summary
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung, ErbB Receptors
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartAug 2015
Primary CompletionMar 2019
Study CompletionApr 2019
TodayJul 2026
First PostedAug 3, 2015
Enrollment StartAug 18, 2015
Primary CompletionMar 28, 2019
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.9 years ago
Interventions
Afatinibdrug
afatinib starting at 30 mg daily dose